Oncoustics is a Canadian medical technology company headquartered in Toronto, Ontario. The company develops AI-powered software solutions that transform low-cost, point-of-care ultrasound devices into diagnostic tools for detecting and monitoring diseases affecting internal organs, with a particular focus on the liver. By leveraging advances in artificial intelligence and signal processing, Oncoustics aims to make surveillance and early detection of chronic and life-threatening diseases more accessible, affordable, and available at the point of care.
The company's core mission is to address the significant gap in early disease detection, especially for conditions like liver disease, which often progress silently and are frequently diagnosed only at advanced stages. By enabling non-invasive, low-cost assessments using widely available ultrasound hardware, Oncoustics seeks to bring specialist-level diagnostic capabilities to primary care settings and underserved regions.
What the Company Does
Oncoustics builds novel AI applications that analyze raw ultrasound data to identify tissue characteristics and disease markers that are typically invisible to the human eye or require expensive imaging modalities and invasive procedures such as biopsies. The company's technology focuses on extracting quantitative, actionable information from ultrasound signals rather than relying solely on conventional image interpretation.
A key differentiator of Oncoustics is its approach to working with inexpensive, portable ultrasound probes. Rather than requiring high-end imaging systems operated by specialists, the company's software is designed to work with affordable point-of-care ultrasound (POCUS) devices. This allows for disease detection and monitoring to be performed by non-specialists, including primary care physicians, nurses, and technicians, dramatically expanding access to diagnostic screening.
The technology captures ultrasound signals and applies proprietary machine learning algorithms and signal analysis to detect and quantify disease-related tissue changes. This enables surveillance workflows that can be repeated frequently and affordably, supporting early detection and ongoing monitoring of chronic conditions.
Focus on Liver Disease
Oncoustics has placed particular emphasis on liver disease, an area of substantial unmet medical need. Chronic liver diseases, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis, affect a large and growing portion of the global population. These conditions are often asymptomatic in early stages and are typically diagnosed through expensive imaging, specialized elastography equipment, or invasive liver biopsy.
By providing a low-cost, non-invasive alternative for assessing liver health, Oncoustics aims to enable earlier intervention, better patient monitoring, and reduced reliance on costly and uncomfortable diagnostic procedures. The ability to screen at-risk populations at the primary care level can help identify disease progression before it reaches critical stages.
Products and Services
AI-Powered Diagnostic Software
Oncoustics' primary offering is its suite of AI-driven software applications that turn standard ultrasound signals into quantitative diagnostic assessments. The software analyzes raw radiofrequency ultrasound data and applies proprietary algorithms to detect tissue abnormalities and disease markers.
Point-of-Care Solutions
The company's solutions are designed to operate with low-cost, portable ultrasound devices, making them suitable for deployment in primary care clinics, community health settings, and resource-limited environments. This point-of-care approach removes the need for specialized imaging centers and expensive equipment.
Disease Surveillance and Monitoring
Oncoustics enables repeatable, non-invasive surveillance workflows that support the ongoing monitoring of patients with chronic conditions. This is particularly valuable for tracking disease progression over time and evaluating the effectiveness of treatments.
Platform Technology
The underlying technology platform is designed to be extensible across multiple organs and disease areas. While the initial focus has been on the liver, the same fundamental approach of applying AI to ultrasound signals has the potential to address a broad range of conditions affecting other organs and tissues.
Technology and Approach
At the heart of Oncoustics' work is the combination of deep learning and advanced signal processing applied to ultrasound data. Traditional ultrasound imaging relies on producing visual images that must be interpreted by trained radiologists or sonographers. Oncoustics takes a different path by analyzing the underlying signal data directly, extracting patterns and features that correlate with specific tissue states and disease conditions.
This data-driven methodology allows the software to deliver consistent, objective, and quantitative results that do not depend on the subjective interpretation of images or the presence of a specialist. By training its algorithms on clinical data, Oncoustics develops models capable of recognizing subtle indicators of disease that can guide clinical decision-making.
Market and Impact
The healthcare industry faces mounting challenges related to the cost and accessibility of diagnostic services. Many diseases that could be managed effectively if caught early instead progress to advanced stages because screening tools are too expensive, too invasive, or unavailable in primary care and rural settings.
Oncoustics addresses these challenges by lowering the barriers to disease detection. Its technology has the potential to reduce healthcare costs by minimizing the need for expensive imaging, specialist referrals, and invasive biopsies. It also supports population health initiatives by making mass screening more feasible, which can lead to earlier diagnoses and improved patient outcomes.
The company's focus on affordability and accessibility aligns with broader trends in healthcare toward decentralization, preventive care, and the democratization of advanced diagnostic capabilities.
Company Background
Oncoustics was founded by a team combining expertise in artificial intelligence, signal processing, medical imaging, and clinical medicine. The company brings together data scientists, engineers, and healthcare professionals united by the goal of making advanced diagnostics accessible to everyone. As a Canadian MedTech startup, Oncoustics operates within a growing ecosystem of health technology innovation in Canada and collaborates with clinical partners to validate and advance its technology.
Conclusion
Oncoustics represents a forward-looking approach to medical diagnostics, using artificial intelligence to unlock the diagnostic potential of low-cost ultrasound hardware. By focusing on non-invasive, affordable, and accessible disease detection, the company is working to close critical gaps in early diagnosis and surveillance, beginning with liver disease and building a platform with the potential to extend across many other medical conditions. Its work embodies the promise of AI-driven MedTech to improve patient care while reducing the burden on healthcare systems.
